By restricting activation of 4-1BB to cells with CLDN18.2 positivity, the hope was to achieve targeted anti-tumor activity with a decreased potential for hepatotoxicity, which had previously occurred in patients treated with urelumab and utomilumab, 4-1BB agnostic mAbs [54,55]. Here, CLDN18 is linked to neoplasm.